Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)
Phase I Study of an Oncofetal Antigen (OFA) Multi-Peptide Immunotherapy (BBMPI03) in Subjects With Hematologic Cancer
Sponsor: Benovus Bio, Inc.
Listed as NCT02240537, this PHASE1 trial focuses on Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM) and remains ongoing. Sponsored by Benovus Bio, Inc., it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Benovus Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .